Convergence Investment Partners, LLC reported INVESCO LTD SHS (IVZ) in 19 quarterly 13F filings from 2025 Q3 through 2026 Q1. Peak portfolio weight reached 0.71% in 2025 Q4. The latest visible filing shows IVZ at 0.71% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Convergence Investment Partners, LLC's position in INVESCO LTD SHS, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
IVZ was reported at 0.71% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q2 — sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Convergence Investment Partners, LLC reported IVZ across 3 quarterly 13F filings, from 2025 Q3 through 2026 Q1.
The largest reported portfolio weight for IVZ was 0.71% in 2025 Q4.
The most recent filing on this page is 2026 Q1, when Convergence Investment Partners, LLC reported 178,323 shares, equal to 0.71% of portfolio, with an estimated market value of $4.3M.
The chart compares Convergence Investment Partners, LLC's quarterly IVZ portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.
Based on 13F filing dates vs. subsequent IVZ price moves, Convergence Investment Partners, LLC correctly timed 10 out of 18 reported position changes (56%). The annualised alpha on IVZ relative to SPY over the holding period was -60.9%.